3 products found

NeoGenomics Laboratories products

RaDaR Residual Disease and Recurrence

RaDaR™ is a personalized, multi-tumor liquid biopsy assay that can track a set of up to 48 tumor-specific variants in a patient using a liquid biopsy with exceptional sensitivity. This allows RaDaR™ to detect traces of molecular residual disease (MRD) in a patient following surgery or other treatment for cancer, enabling early detection of relapse and accurate monitoring.

InVisionFirst®-Lung

InVisionFirst®-Lung, a ctDNA NGS liquid biopsy testing 37 genes relevant to the care of patients with advanced NSCLC. Covered for Medicare and other private insurance NSCLC patients who meet specific clinical criteria in the United States. InVisionFirst-Lung® is available world-wide for both commercial and research use.

InVisionSeq

InVisionSeq™ is a qualitative laboratory developed test that uses targeted advanced sequencing technology to detect single nucleotide variants (SNVs), copy number variants (CNVs), insertions and deletions (InDels) in selected genes from DNA isolated from plasma samples from patients. InVisionSeq™ is available world-wide for both commercial and research use for a range of cancer types. This test is not reimbursed in the US.